查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566842

滤泡刺激素市场：按类型、应用和最终用户分类：2024-2033 年全球机会分析和产业预测

Follicle Stimulating Hormone Market By Type , By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

滤泡刺激素市场

2023年，滤泡刺激素市值为19.4亿美元，预计到2035年将达到37.4亿美元，2024年至2035年的复合年增长率为5.7%。

滤泡刺激素（FSH）是脑下垂体产生的一种重要激素，在生殖健康中发挥重要作用。对于女性来说，FSH 特别参与月经週期和卵巢功能，因为它刺激含卵子卵泡的发育。 FSH 进一步调节雌激素和黄体素的产生，这两种激素与月经週期和怀孕有关。对于男性来说，这种荷尔蒙会刺激睪丸中精子细胞的产生。它与黄体激素(LH) 一起有助于调节生育能力和正常生殖功能。除了生殖功能外，FSH 还影响骨骼健康，对于卵巢症候群 (PCOS) 和不孕症等疾病至关重要。

不孕症盛行率的增加以及个人对基于 FSH 的药物益处的认识不断提高是推动滤泡刺激素市场成长的关键因素。此外，辅助生殖技术（ART）的日益普及预计也将显着促进市场成长。目前，FSH 在子宫内膜干细胞再生相关功能的探索正在受到关注。据科学家称，预计这将提高女性的怀孕率。

然而，某些地区的保险不涵盖与不孕症治疗相关的治疗，包括 FSH 治疗。这使得此类治疗变得昂贵，导致无法获得此类治疗并抑制市场开拓。此外，在某些情况下，使用 FSH 的副作用可能很严重，包括多胎妊娠、卵巢过度刺激症候群 (OHSS) 和荷尔蒙失衡。这限制了FSF的使用，并对市场相关人员提出了挑战。相反，由于生活方式的改变和环境压力，全球不孕率正在迅速上升。根据美国疾病管制与预防中心 2023 年的论文，15 岁至 49 岁之间的女性中有 13.4% 患有不孕症。这些统计数据显示这个市场的未来是充满希望的。

分部概览

滤泡刺激素市场按类型、应用、最终用户和地区细分。依类型，市场分为重组 FSH 和尿 FSH。依应用范围分为不孕症治疗和辅助生殖技术。依最终用户划分，可分为医院、生育诊所和冷冻库。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，重组 FSH 细分市场在 2023 年占据主导地位。

从应用来看，不孕症治疗领域在2023年获得了较高的市场占有率。

按地区划分，北美地区 2023 年收益最高。

可以使用此报告进行客製化（需要额外费用和时间表）

  • 按产品/细分市场分類的参与企业市场占有率分析
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 平均售价分析/价格分布分析
  • 扩大公司简介列表
  • 历史市场资料

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章滤泡刺激素市场：依类型

  • 市场概况
  • 基因改造FSH
  • 尿促卵泡刺激素

第五章滤泡刺激素市场：依应用分类

  • 市场概况
  • 不孕症治疗
  • 辅助生殖技术

第六章滤泡刺激素市场：依最终用户分类

  • 市场概况
  • 医院
  • 不孕不育治疗诊所
  • 冷冻库

第七章滤泡刺激素市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国滤泡刺激素市场
    • 加拿大滤泡刺激素市场
    • 墨西哥滤泡刺激素市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国滤泡刺激素市场
    • 法国滤泡刺激素市场
    • 英国滤泡刺激素市场
    • 义大利滤泡刺激素市场
    • 西班牙滤泡刺激素市场
    • 其他欧洲滤泡刺激素市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本滤泡刺激素市场
    • 中国滤泡刺激素市场
    • 澳洲滤泡刺激素市场
    • 印度滤泡刺激素市场
    • 韩国滤泡刺激素市场
    • 其他亚太地区滤泡刺激素市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西滤泡刺激素市场
    • 沙特滤泡刺激素市场
    • 南非滤泡刺激素市场
    • 其他拉丁美洲/中东/非洲滤泡刺激素市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Pfizer Inc.
  • Novartis AG
  • Abbott Laboratories
  • Sanofi SA
  • Boehringer Ingelheim GmbH
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Zydus Lifesciences Limited
简介目录
Product Code: A65456

Follicle Stimulating Hormone Market

The follicle stimulating hormone market was valued at $1.94 billion in 2023 and is estimated to reach $3.74 billion by 2035, exhibiting a CAGR of 5.7% from 2024 to 2035.

Follicle stimulating hormone (FSH) is a vital hormone produced by the pituitary gland that plays a key role in reproductive health. In females, FSH is specifically involved in the menstrual cycle and ovarian function as it stimulates the development of ovarian follicles containing the ovum. FSH further regulates the production of two essential hormones involved in menstrual cycle and pregnancy that are estrogen and progesterone. In males, the hormone stimulates sperm cells production in the testes. It works alongside luteinizing hormone (LH) to regulate fertility and normal reproductive functions. Along with its reproductive functions, FSH impacts the bone health and is essential in conditions such as polycystic ovary syndrome (PCOS) and infertility.

Increase in prevalence of infertility and rise in awareness among individuals regarding the benefits of FSH-based medications are the key factors driving the growth of the follicle stimulating hormone market. Moreover, increase in adoption of assisted reproductive technology (ART) is expected to significantly augment the growth of the market. Currently, the exploration of FSH in several regeneration-related functions of endometrial stem cells is acquiring traction. According to scientists, this is predicted to subsequently increase pregnancy rates among females.

However, fertility-related treatments, including FSH therapies, are not covered under insurance policies in several regions. This makes such treatments expensive for several individuals, thus preventing them from undergoing such treatments and restraining the market development. Moreover, the side-effects of FSH administration are severe in some cases, including multiple pregnancies, ovarian hyperstimulation syndrome (OHSS), and hormonal imbalances. This limits the utilization of FSF and presents challenges for the market players. On the contrary, infertility rates are surging globally owing to lifestyle changes and environmental stressors. As per a 2023 article by Center of Disease Control and Prevention, 13.4% of women between the age 15-49 were reported to suffer from impaired fecundity. These statistics indicate a promising future for the market.

Segment Overview

The follicle stimulating hormone market is segmented into type, application, end user, and region. On the basis of type, the market is bifurcated into recombinant FSH and urinary FSH. By application, it is classified into infertility treatment and assisted reproductive technology. As per end user, it is categorized into hospitals, fertility clinics, and cryobanks. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the recombinant FSH segment dominated the market in 2023.

By application, the infertility treatment segment acquired a high market share in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players operating in the follicle stimulating hormone market are Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Merck Specialities Pvt Ltd., Intas Pharmaceuticals Ltd., and Cipla Ltd. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Market share analysis of players by products/segments
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Type

  • Recombinant FSH
  • Urinary FSH

By Application

  • Infertility Treatment
  • Assisted Reproductive Technology

By End User

  • Hospitals
  • Fertility Clinics
  • Cryobanks

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • Novartis AG
    • Abbott Laboratories
    • Sanofi S.A.
    • Boehringer Ingelheim GmbH
    • Merck KGaA
    • Teva Pharmaceutical Industries Ltd.
    • Intas Pharmaceuticals Ltd.
    • Cipla Ltd.
    • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: FOLLICLE STIMULATING HORMONE MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Recombinant FSH
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Urinary FSH
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Infertility Treatment
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Assisted Reproductive Technology
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: FOLLICLE STIMULATING HORMONE MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Fertility Clinics
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Cryobanks
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: FOLLICLE STIMULATING HORMONE MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Follicle Stimulating Hormone Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Follicle Stimulating Hormone Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Follicle Stimulating Hormone Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Follicle Stimulating Hormone Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Follicle Stimulating Hormone Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Follicle Stimulating Hormone Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Follicle Stimulating Hormone Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Follicle Stimulating Hormone Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Follicle Stimulating Hormone Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Follicle Stimulating Hormone Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Follicle Stimulating Hormone Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. Australia Follicle Stimulating Hormone Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. India Follicle Stimulating Hormone Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Follicle Stimulating Hormone Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Follicle Stimulating Hormone Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Follicle Stimulating Hormone Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Follicle Stimulating Hormone Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Follicle Stimulating Hormone Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Follicle Stimulating Hormone Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Pfizer Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Abbott Laboratories
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Sanofi S.A.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Boehringer Ingelheim GmbH
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Merck KGaA
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Teva Pharmaceutical Industries Ltd.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Intas Pharmaceuticals Ltd.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Cipla Ltd.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Zydus Lifesciences Limited
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments